Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 11/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6442423 | 0.86 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3MAPT | |
| SCHEMBL5044517 | 0.80 | APP (0.53) | ADORA2AADORA1ADORA2BADORA3MAPT | |
| SCHEMBL6441631 | 0.77 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BMAPTHPGD | |
| SCHEMBL29623271 | 0.76 | ADORA2A (0.58) | ADORA2AADORA1ADORA2BADORA3TP53 | |
| SCHEMBL6443406 | 0.72 | ADORA2A (0.64) | ADORA2AADORA1ADORA2BMAPTHPGD | |
| SCHEMBL7400282 | 0.72 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BMAPTHPGD | |
| SCHEMBL6443198 | 0.71 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BADORA3MAPT | |
| SCHEMBL7403371 | 0.70 | ADORA2A (0.55) | ADORA2AADORA1ADORA2BADORA3MAPT | |
| SCHEMBL23162564 | 0.70 | ADORA2A (0.60) | ADORA2AADORA1ADORA2BADORA3MAPT | |
| SCHEMBL5044568 | 0.69 | ALDH1A1 (0.57) | ADORA2AADORA1ADORA2BADORA3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | claimed |
| EP-4038065-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | claimed |
| WO-2021063852-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | claimed |
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4038065-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | disclosed |
| WO-2021063852-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021063852-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396567-A1 | SUBSTITUTED PYRIMIDINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | TYMP, HPRT1, DPYD | ADORA2A 41/4885ADORA1 28/4885ADORA2B 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.